Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Kossen (Cambridge, United States of America), C. Schaefer (Cambridge, United States of America), S. Lim (Cambridge, United States of America), M. Michener (Cambridge, United States of America), P. Ruminiski (Cambridge, United States of America), D. Griggs (Cambridge, United States of America), R. Radhakrishnan (Cambridge, United States of America), B. Bradford (Cambridge, United States of America), S. Seiwert (Cambridge, United States of America). IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF. 5374

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005 Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013 Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007 Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Inhibitory effect of PGE2 receptor subtype, EP4, in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007 Role of leukotriene receptor antagonist on TGF-β1 and Smad signalling in bleomycin induced pulmonary fibrosis Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids Source: Eur Respir J, 50 (2) 1700670; 10.1183/13993003.00670-2017 Year: 2017 Biosynthesis and implementation of Thyroid Receptor beta (TRß) agonists (thyromimetics) for the treatment of pulmonary fibrosis Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021 Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004 Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Source: Eur Respir J 2008; 32: 426-436 Year: 2008 Protective effect of a Protein Epitope Mimetic (PEM) CXCR4 antagonist, POL5551, in an allergic model of asthma Source: Annual Congress 2010 - Models of airways disease Year: 2010